Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities

Oncogene

Volumn 33, Issue 5, 2014, Pages 550-555

  Patel, R A ^a   Liu, Y ^a   Wang, B ^a   Li, R ^a   Sebti, S M ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

invasion; migration; MLC 2; RKI 18; ROCK1; ROCK2

Indexed keywords

3T3 CELLS; ACTINS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARDIAC MYOSINS; CELL LINE, TUMOR; CELL MOVEMENT; CYTOSKELETON; HUMANS; MICE; MYOSIN LIGHT CHAINS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; P21-ACTIVATED KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 84895070483     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.634     Document Type: Article

References (33)

1. Amano M, Fukata Y, Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp Cell Res 2000; 261: 44-51.
2. Somlyo AP, Somlyo AV. Ca2 sensitivity of smooth muscle and nonmuscle myosin II: Modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003; 83: 1325-1358.
3. Zicha D, Dobbie IM, Holt MR, Monypenny J, Soong DY, Gray C et al. Rapid actin transport during cell protrusion. Science 2003; 300: 142-145.
4. Redowicz MJ. Rho-associated kinase: Involvement in the cytoskeleton regulation. Arch Biochem Biophys 1999; 364: 122-124.
5. Tang Y, Olufemi L, Wang MT, Nie D. Role of Rho GTPases in breast cancer. Front Biosci 2008; 13: 759-776.
6. Riento K, Ridley AJ. Rocks: Multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003; 4: 446-456.
7. Olson MF. Applications for ROCK kinase inhibition. Curr Opin Cell Biol 2008; 20: 242-248.
8. Olson MF, Sahai E. The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis 2009; 26: 273-287.
9. Scott RW, Olson MF. LIM kinases: Function, regulation and association with human disease. J Mol Med (Berl) 2007; 85: 555-568.
10. Liu S, Goldstein RH, Scepansky EM, Rosenblatt M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res 2009; 69: 8742-8751.
11. Lane J, Martin TA, Watkins G, Mansel RE, Jiang WG. The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int J Oncol 2008; 33: 585-593.
12. Routhier A, Astuccio M, Lahey D, Monfredo N, Johnson A, Callahan W et al. Pharmacological inhibition of Rho-kinase signaling with Y-27632 blocks melanoma tumor growth. Oncol Rep 2010; 23: 861-867.
13. Ying H, Biroc SL, Li WW, Alicke B, Xuan JA, Pagila R et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 2006; 5: 2158-2164.
14. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 1999; 5: 221-225.
15. Imamura F, Mukai M, Ayaki M, Akedo H. Y-27632, an inhibitor of rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase. Jpn J Cancer Res 2000; 91: 811-816.
16. Wyckoff JB, Pinner SE, Gschmeissner S, Condeelis JS, Sahai E. ROCK-and myosindependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr Biol 2006; 16: 1515-1523.
17. Yoshioka K, Foletta V, Bernard O, Itoh K. A role for LIM kinase in cancer invasion. Proc Natl Acad Sci USA 2003; 100: 7247-7252.
18. Bourguignon LY, Zhu H, Shao L, Zhu D, Chen YW. Rho-kinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motil Cytoskeleton 1999; 43: 269-287.
19. Li B, Zhao WD, Tan ZM, Fang WG, Zhu L, Chen YH. Involvement of Rho/ROCK signalling in small cell lung cancer migration through human brain microvascular endothelial cells. FEBS Lett 2006; 580: 4252-4260.
20. Yoshioka K, Nakamori S, Itoh K. Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Cancer Res 1999; 59: 2004-2010.
21. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000; 406: 532-535.
22. Ridley AJ. Rho proteins and cancer. Breast Cancer Res Treat 2004; 84: 13-19.
23. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002; 2: 133-142.
24. Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 1999; 81: 682-687.
25. Burbelo P, Wellstein A, Pestell RG. Altered Rho GTPase signaling pathways in breast cancer cells. Breast Cancer Res Treat 2004; 84: 43-48.
26. Suwa H, Ohshio G, Imamura T, Watanabe G, Arii S, Imamura M et al. Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 1998; 77: 147-152.
27. Kleer CG, Van Golen KL, Zhang Y, Wu ZF, Rubin MA, Merajver SD. Characterization of RhoC expression in benign and malignant breast disease: A potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 2002; 160: 579-584.
28. Li R, Martin MP, Liu Y, Wang B, Patel RA, Zhu JY et al. Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors. J Med Chem 2012; 55: 2474-2478.
29. Slack-Davis JK, Eblen ST, Zecevic M, Boerner SA, Tarcsafalvi A, Diaz HB et al. PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation. J Cell Biol 2003; 162: 281-291.
30. Bishop AL, Hall A. Rho GTPases and their effector proteins. Biochem J 2000; 348: 241-255.
31. Patel RA, Forinash KD, Pireddu R, Sun Y, Sun N, Martin MP et al. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res 2012; 72: 5025-5034.
32. Vigil D, Kim TY, Plachco A, Garton AJ, Castaldo L, Pachter JA et al. ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage- independent growth and invasion. Cancer Res 2012; 72: 5338-5347.
33. Balasis ME, Forinash KD, Chen YA, Fulp WJ, Coppola D, Hamilton AD et al. Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. Clin Cancer Res 2011; 17: 2852-2862.